Corbus Pharmaceuticals Holdings, Inc.
- Open
- 9.29
- Day high
- 9.45
- Day low
- 8.99
- Prev close
- 9.38
- Volume
- 104K
- Mkt cap
- $166M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.3
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $28K over the last 3 months (2 open-market buys, 3 sales)
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a Healthcare company listed on NASDAQ. The stock is up 30% over the past year. Over the trailing 3 months, insiders filed 2 open-market buys and 3 sales (SEC Form 4).
Corbus Pharmaceuticals Holdings, Inc. (CRBP) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CRBP earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 12, 2026 | $-1.26 | $-1.23 | +2.4% | — | — |
| Mar 9, 2026 | $-1.52 | $-1.25 | +17.6% | — | — |
| Nov 12, 2025 | $-1.80 | $-1.90 | -5.6% | — | — |
| Mar 11, 2025 | $-1.02 | $-0.78 | +23.5% | — | — |
| Nov 7, 2024 | $-0.99 | $-1.15 | -16.2% | — | — |
| Mar 12, 2024 | $-2.36 | $-1.81 | +23.3% | $1M | — |
| Mar 7, 2023 | $-2.10 | $-2.61 | -24.3% | — | — |
| Mar 8, 2022 | $-3.30 | $-2.40 | +27.3% | $-881705 | -353.7% |
| Nov 12, 2021 | $-3.60 | $-0.60 | +83.3% | $97323 | -84.0% |
| Aug 12, 2021 | $-3.60 | $-4.50 | -25.0% | $136558 | -0.3% |
| May 13, 2021 | $-4.50 | $-4.20 | +6.7% | $647824 | -6.2% |
| Mar 15, 2021 | $-6.61 | $-3.00 | +54.6% | $658204 | — |
CRBP insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 11, 2026 | Kung Winstondirector | Sell | 2,026 | $7.91 |
| Jun 11, 2026 | Altmeyer Annedirector | Sell | 2,412 | $7.91 |
| Jun 11, 2026 | Jenkins John Kennethdirector | Sell | 4,800 | $7.91 |
| Jun 3, 2026 | Saxena Nishant Cofficer: Chief Business Officer | Buy | 4,500 | $7.33 |
| Jun 3, 2026 | Saxena Nishant Cofficer: Chief Business Officer | Buy | 9,000 | $7.58 |
| May 22, 2026 | Saxena Nishant Cofficer: Chief Business Officer | Grant | 192,300 | $11.51 |
| May 22, 2026 | Saxena Nishant Cofficer: Chief Business Officer | Grant | 58,300 | — |
| May 21, 2026 | Ben Yongdirector | Grant | 12,300 | $9.15 |
| May 21, 2026 | Pfeiffenberger Brentdirector | Grant | 24,700 | $9.15 |
| May 21, 2026 | Jenkins John Kennethdirector | Grant | 12,300 | $9.15 |
| May 21, 2026 | Jenkins John Kennethdirector | Grant | 3,800 | — |
| May 21, 2026 | Kung Winstondirector | Grant | 3,800 | — |
| May 21, 2026 | Jacques Rachelle Suzannedirector | Grant | 3,800 | — |
| May 21, 2026 | Jacques Rachelle Suzannedirector | Grant | 12,300 | $9.15 |
| May 21, 2026 | Pfeiffenberger Brentdirector | Grant | 7,500 | — |
Source: CRBP SEC Form 4 filings, latest Jun 11, 2026. For informational purposes only — not investment advice.
See the full CRBP insider & 13F page →Corbus Pharmaceuticals Holdings, Inc. company profile
Overview
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a biopharmaceutical company founded in 2009 and headquartered in Norwood, Massachusetts. The company went public in October 2014 and focuses on developing innovative immune modulators for treating immuno-oncology and fibrosis diseases. Corbus operates as a clinical-stage biotechnology company, meaning it is primarily engaged in research and development activities rather than commercial product sales, with multiple drug candidates in various stages of clinical trials.
Business
Corbus Pharmaceuticals operates in the biotechnology sector, specifically focusing on developing therapeutic drugs that modulate the immune system. The company's core expertise lies in creating molecules that can either enhance or suppress immune responses to treat cancer and fibrotic diseases. The company's primary drug candidate is lenabasum, an oral medication that selectively activates cannabinoid receptor type 2 (CB2). This receptor is part of the body's endocannabinoid system, which helps regulate immune responses and inflammation. Lenabasum is currently in Phase II clinical trials for treating systemic lupus erythematosus, an autoimmune disease where the body's immune system attacks its own tissues. Beyond lenabasum, Corbus is developing two monoclonal antibody programs: CRB-601 and CRB-602. Both are anti-integrin monoclonal antibodies designed to inhibit transforming growth factor β (TGFβ), a protein that plays a crucial role in tissue scarring and cancer progression. CRB-601 targets cancer and fibrosis treatment, while CRB-602 specifically focuses on fibrotic diseases, which involve excessive scarring of organs like the lungs, heart, kidneys, and liver. The company also has a cannabinoid receptor type 1 inverse agonist program in development for metabolic disorders including obesity, diabetic complications, and nonalcoholic steatohepatitis (fatty liver disease). Through a licensing agreement with Jenrin Discovery, LLC, Corbus has access to a library of approximately 600 compounds and related patent filings, expanding its drug development pipeline.
Revenue model
As a clinical-stage biotechnology company, Corbus Pharmaceuticals currently generates no revenue from product sales. The company operates on a research and development model, funded primarily through equity financing, grants, and potential partnership deals. Biotechnology companies like Corbus typically monetize their investments through several potential pathways: licensing agreements with larger pharmaceutical companies, outright sale of drug candidates or the entire company, or eventual commercialization of approved drugs. The company's path to profitability depends entirely on successful clinical trial outcomes and regulatory approvals. If lenabasum or other drug candidates successfully complete clinical trials and receive FDA approval, Corbus could generate revenue through direct sales, licensing fees, or royalty payments from pharmaceutical partners. The company's financial sustainability is currently dependent on its ability to raise capital through equity offerings or secure strategic partnerships. Several factors could significantly impact Corbus's future margins and success. Positive clinical trial results would dramatically increase the company's valuation and partnership opportunities, while negative results could severely impact funding and viability. The competitive landscape in immune modulators and fibrosis treatments is intense, with larger pharmaceutical companies and other biotechnology firms developing similar therapies. Regulatory changes in drug approval processes, healthcare reimbursement policies, and the overall biotechnology investment climate also significantly influence the company's prospects. Additionally, the company's burn rate and ability to manage cash resources effectively determine how long it can sustain operations before needing additional funding or achieving revenue-generating milestones.
Competitive moat
Corbus Pharmaceuticals operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages. The company's primary potential moat lies in its intellectual property portfolio, particularly around its CB2 receptor activation technology and the licensed compound library from Jenrin Discovery. However, this moat is relatively narrow and time-limited, as patents eventually expire and other companies can develop alternative approaches to target similar biological pathways. The company's expertise in cannabinoid receptor modulation provides some differentiation, as this represents a less crowded therapeutic approach compared to traditional immune modulators. The selective CB2 activation mechanism of lenabasum could offer advantages in terms of reduced side effects compared to broader immune suppressants, potentially creating a competitive edge if clinical trials demonstrate superior safety profiles. However, Corbus faces significant competitive threats from larger pharmaceutical companies with substantially greater resources, established commercial infrastructure, and diversified pipelines. Companies like Gilead Sciences, Bristol Myers Squibb, and Roche have extensive experience in immunology and oncology, with the financial capacity to rapidly advance competing therapies. Additionally, the biotechnology sector's rapid pace of innovation means that novel therapeutic approaches could emerge that render Corbus's current pipeline obsolete. The company's small size and limited financial resources create vulnerability to well-funded competitors who can conduct larger, faster clinical trials or acquire promising assets. Without strong clinical trial results or strategic partnerships, Corbus lacks the sustainable competitive advantages necessary to maintain long-term market position in the highly competitive biotechnology industry.
Risks & safety
Corbus Pharmaceuticals presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong liquidity but significant operational risks. • Cash and Liquidity: The company maintains a strong current ratio of 11.8x and quick ratio of 11.8x as of Q1 2025, with $18.9 million in cash and short-term investments against $11.6 million in current liabilities. • Debt Position: Minimal debt burden with debt-to-equity ratio of only 0.022, indicating low financial leverage and reduced solvency risk from debt obligations. • Cash Burn: Significant concern with quarterly operating cash flow burn of approximately $16.4 million in Q1 2025, suggesting the current cash position may only sustain operations for 1-2 quarters without additional funding. • Valuation Metrics: Trading at 0.51x price-to-book ratio, indicating the stock trades below tangible book value, though this is partly due to accumulated losses and limited tangible assets. • Revenue Generation: Zero revenue generation creates substantial risk, as the company is entirely dependent on successful clinical trials and future monetization events. • Other Considerations: The company's substantial net current assets relative to market capitalization (Graham net-net ratio of 0.50) provides some downside protection, but the ongoing cash burn and binary nature of drug development outcomes create significant execution risk.
Recent development
Based on the available financial data, Corbus Pharmaceuticals has been navigating the challenging landscape of clinical-stage drug development over recent years. The company has maintained its focus on advancing its core pipeline, particularly lenabasum for systemic lupus erythematosus, while managing cash resources through what appears to be a significant equity raise that boosted its balance sheet substantially between 2023 and 2024. The most notable development has been the dramatic improvement in the company's financial position, with total current assets increasing from $23.5 million at the end of 2023 to $153.0 million by the end of 2024. This substantial capital infusion, likely through equity financing, has provided the company with additional runway to advance its clinical programs. However, the company has also experienced increased quarterly cash burn, with operating cash flow losses escalating from approximately $9-10 million per quarter in 2024 to over $16 million in Q1 2025. The company has maintained its strategic focus on immune modulation and fibrosis treatments, continuing to advance its monoclonal antibody programs CRB-601 and CRB-602 alongside its lead candidate lenabasum. The licensing agreement with Jenrin Discovery remains a key component of the company's pipeline expansion strategy, providing access to a broader library of potential therapeutic compounds. Throughout this period, Corbus has maintained minimal debt levels and strong liquidity ratios, positioning itself to weather the inherent volatility of clinical-stage biotechnology development while pursuing its regulatory and commercial objectives.
CRBP company profile · for informational purposes only — not investment advice.
Track CRBP with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free